PTC
TRDA icon

Private Trust Company’s Entrada Therapeutics TRDA Stock Holding History

Private Trust Company’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,013
Closed -$9.16K – 2584
2025
Q1 		$9.16K Hold
1,013
– – ﹤0.01% 1831
2024
Q4 		$17.5K Hold
1,013
– – ﹤0.01% 1528
2024
Q3 		$16.2K Buy
+1,013
New +$16K ﹤0.01% 1545

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Private Trust Company's TRDA Position: Q2 2025 in Review

Private Trust Company sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 1,013 shares — an estimated $9.16K sold.

Private Trust Company first reported a position in TRDA in Q3 2024 and held it in 3 quarters. The position peaked at $17.5K in Q4 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • Private Trust Company reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Private Trust Company sold 1,013 Entrada Therapeutics shares in Q2 2025, an estimated $9.16K.
  • Private Trust Company first reported a position in Entrada Therapeutics in Q3 2024 and held it in 3 quarters.
  • Private Trust Company's Entrada Therapeutics position peaked at $17.5K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on Private Trust Company's 13F filing for Q2 2025, filed 29 Jul 2025.